Welcome to our dedicated page for Mereo Biopharma news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo Biopharma stock.
Mereo Biopharma Group plc (MREO) is a clinical-stage biopharmaceutical leader developing innovative treatments for rare diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical progress, strategic partnerships, and regulatory developments.
Our curated collection features official press releases and verified news covering critical milestones including clinical trial results, regulatory submissions, and strategic collaborations. Track updates across Mereo's pipeline targeting conditions like osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.
All content undergoes rigorous verification to ensure accuracy and relevance. For comprehensive tracking of Mereo's progress in rare disease therapeutics, bookmark this page for direct access to primary source materials and expert analysis of corporate developments.
Mereo BioPharma Group plc (NASDAQ: MREO) announced that the FDA granted Orphan Drug Designation to alvelestat for treating alpha-1 antitrypsin deficiency (AATD). This designation highlights the urgent need for therapies addressing this rare, life-threatening condition. Alvelestat, currently in a Phase 2 clinical trial, aims to protect patients from lung damage caused by neutrophil elastase. The Orphan Drug Designation offers various incentives, including seven-year market exclusivity upon approval. Mereo plans to update its program by year-end 2021.
Mereo BioPharma (MREO) presented secondary endpoint data from the Phase 2b ASTEROID study for UX143 (setrusumab) at the ASBMR 2021 Annual Meeting. The study revealed a statistically significant bone-building effect in Osteogenesis Imperfecta (OI) patients, with an 8.97% increase in lumbar spine bone mineral density at 12 months in the highest dose cohort. Improvements in bone strength at the wrist and tibia were also observed. Following these results, Mereo BioPharma and Ultragenyx plan to advance UX143 into late-stage development for various OI subtypes.
Mereo BioPharma Group plc (NASDAQ: MREO) has appointed Pierre Jacquet, M.D., Ph.D. to its Board of Directors as of September 20, 2021. Dr. Jacquet brings over 20 years of experience in life sciences and strategy, previously serving as Managing Director at L.E.K. Consulting. His expertise is expected to enhance the company's clinical portfolio development. Concurrently, Peter Bains has retired from the Board after over six years of service. Mereo focuses on innovative therapies for oncology and rare diseases, with product candidates in various stages of clinical trials.
Mereo BioPharma Group plc (NASDAQ: MREO) announced participation in three investor conferences in September 2021. These include the Morgan Stanley 19th Annual Global Healthcare Conference (Sept 13-14), SVB Leerink CybeRx Series (Sept 22-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept 30 at 9:30am ET). A live audio webcast of the fireside chat at the Cantor Fitzgerald event will be available on the Company’s website. Mereo is focused on developing innovative therapeutics for oncology and rare diseases, with notable advances in clinical trials.
Infinity Pharmaceuticals announces the appointment of Robert Ilaria, Jr. as Chief Medical Officer, leading the clinical development of eganelisib, an oral immuno-oncology therapeutic. Ilaria brings extensive oncology experience, notably from his roles at Bristol Myers Squibb and Celgene. Brian Schwartz, previously Consulting Chief Physician, transitions to the Board of Directors. The press release highlights the promising data from ongoing studies, particularly in treating bladder and triple negative breast cancers, with plans for future development and registration studies.
Mereo BioPharma (NASDAQ: MREO) announced that CEO Dr. Denise Scots-Knight will speak at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 9:30 AM ET. A live audio webcast will be available on the Company’s website, with a replay accessible for two weeks.
Mereo focuses on developing therapeutics for oncology and rare diseases, with key products including etigilimab for various tumors and alvelestat for Alpha-1 antitrypsin deficiency. The Company aims to deliver improved health outcomes in these areas.
Mereo BioPharma (NASDAQ: MREO) announced positive interim data from a study of alvelestat for Bronchiolitis Obliterans Syndrome (BOS) post-hematopoietic stem cell transplantation. The Phase 1b/2 study, in collaboration with the National Cancer Institute, aims to recruit 30 patients. Initial results indicated that alvelestat was well tolerated, with six of seven patients showing stable disease. Significant reductions in the desmosine biomarker were observed, suggesting alvelestat's efficacy in inhibiting neutrophil elastase. Further analyses are planned for the upcoming ASH 2021 meeting.
Mereo BioPharma Group plc (NASDAQ: MREO) announced that CEO Dr. Denise Scots-Knight will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on June 3, 2021, at 8:00 AM Eastern Time. Investors can access the live audio webcast on the company’s website, with an archived version available for two weeks post-event. Mereo focuses on developing innovative therapeutics for oncology and rare diseases, boasting a robust pipeline including etigilimab and navicixizumab for cancers, and alvelestat and setrusumab for rare diseases.
Mereo BioPharma Group plc (NASDAQ: MREO) will host a virtual R&D day on May 13, 2021, to discuss its etigilimab (Anti-TIGIT) program, focusing on studies for ovarian, cervical cancer, and sarcoma. The event features key opinion leaders and will include updates on the Phase 1b/2 ACTIVATE study and a collaboration with the Cancer Focus Fund for a clinical trial at MD Anderson Cancer Center. Mereo aims to enhance outcomes in oncology and rare diseases with its advanced product candidates.
FAQ
What is the current stock price of Mereo Biopharma (MREO)?
What is the market cap of Mereo Biopharma (MREO)?
